Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel antithrombotic drugs in development

M Verstraete1, P Zoldhelyi

  • 1Center for Molecular and Vascular Biology, University of Leuven, Belgium.

Drugs
|June 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influencing factors in knee kinematics following posteriorly stabilized knee arthroplasty: a comprehensive analysis.

Acta orthopaedica Belgica·2025
Same author

Trends For Smaller Medical Journals.

Acta clinica Belgica·2016
Same author

Temperature dependence of the electronic structure of semiconductors and insulators.

The Journal of chemical physics·2015
Same author

Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial.

British journal of cancer·2015
Same author

[Update on the management of acute viral bronchiolitis: proposed guidelines of Grand Ouest University Hospitals].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2013
Same author

[Management of bronchiolitis in general practice and determinants of treatment being discordant with guidelines of the HAS].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2013

Aspirin prevents blood clots by inhibiting the arachidonic-thromboxane pathway, but not all platelet activation. New antiplatelet drugs target other pathways, including glycoprotein IIb/IIIa and thrombin, for broader prevention strategies.

Area of Science:

  • Cardiovascular Pharmacology
  • Hematology
  • Thrombosis Research

Background:

  • Platelet activation is crucial in thromboembolic disorders, with aspirin as a primary preventive strategy.
  • Aspirin's efficacy is limited as it only inhibits the arachidonic-thromboxane pathway, not ADP, collagen, or thrombin-induced aggregation.
  • This necessitates exploring eicosanoid-independent effects and alternative antiplatelet drug targets.

Purpose of the Study:

  • To investigate the limitations of aspirin's antiplatelet effects.
  • To explore novel antiplatelet drug targets beyond cyclo-oxygenase inhibition.
  • To review emerging therapeutic strategies for thromboembolic disorders.

Main Methods:

  • Review of existing literature on aspirin's mechanism of action.

Related Experiment Videos

  • Analysis of alternative antiplatelet drug classes targeting different pathways.
  • Examination of novel agents inhibiting glycoprotein IIb/IIIa, thrombin, and factor Xa.

    • Main Results:

    • Aspirin selectively inhibits platelet aggregation via the arachidonic-thromboxane pathway.
    • Emerging drugs target glycoprotein IIb/IIIa, thrombin (directly or indirectly), and factor Xa.
    • Novel agents include RGD mimetics, prostacyclin analogues, and direct thrombin inhibitors.

    Conclusions:

    • Aspirin's targeted action highlights the need for diverse antiplatelet strategies.
    • Targeting glycoprotein IIb/IIIa, thrombin, and factor Xa offers broader therapeutic potential.
    • Further research into these novel agents is critical for advancing thromboembolic disorder prevention.